$100M facility focused on AI in healthcare planned for Manhattan

A new building is soon to rise in New York City inside which will buzz myriad medical research and clinical activities involving AI.  

The Icahn School of Medicine at Mount Sinai announced plans June 11 to open the Hamilton and Amabel James Center for Artificial Intelligence and Human Health in late 2021 with 40 or so principal investigators plus around 250 graduate students, postdoctoral fellows, computer scientists and support staff.

The center takes its name from a couple who are heavily investing in the project, which will cost around $100 million from various sources to get up and running in Upper Manhattan, Bloomberg is reporting.

According to the school’s announcement, the interdisciplinary center will be the first site in New York to integrate AI, data science and routine genomic screening.

Other key areas of concentration will include AI-aided disease modeling and precision imaging.

“Artificial Intelligence and machine learning are spurring innovation across many different fields but perhaps most significantly in healthcare,” investor Hamilton “Tony” James said in prepared remarks. “I am pleased to support [Mount Sinai’s] mission and accelerate the development of cutting-edge therapies and technologies that have the potential to change lives around the world.”

James is executive vice chairman of the New York-based Blackstone Group.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.